<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04929912</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-21-001</org_study_id>
    <nct_id>NCT04929912</nct_id>
  </id_info>
  <brief_title>Electroporation for Cancer Treatment Real World Registry</brief_title>
  <acronym>PIONEER</acronym>
  <official_title>Electroporation for Cancer Treatment Real World Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirai Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirai Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry aims to assess real-world long-term disease outcomes for patients treated using&#xD;
      reversible electroporation and a chemotherapeutic or calcium; in particular tumour response&#xD;
      rates and recurrence rates. The study also aims to characterise side effects and the&#xD;
      occurrence of Adverse Events and their relationship to the treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 24, 2021</start_date>
  <completion_date type="Anticipated">June 24, 2036</completion_date>
  <primary_completion_date type="Anticipated">December 24, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (CTCAE)</measure>
    <time_frame>5 years</time_frame>
    <description>Safety evaluation will be performed via continuous assessment of safety parameters by reviewing events as they arise. The investigation will be put on hold if unacceptable safety issues are outstanding.&#xD;
Adverse Events (AE) and Serious Adverse Events (SAE) will be evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Evaluation Criteria in Solid Tumours (RECIST)</measure>
    <time_frame>3 months, 12 months, 3 years, 5 years</time_frame>
    <description>A response evaluation will be conducted at standard of care follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified FACE-Q evaluation for Skin Cancers</measure>
    <time_frame>3 months, 12 months, 3 years, 5 years</time_frame>
    <description>Cosmesis evaluation will be recorded for skin cancers at standard of care follow up</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Skin Cancer</condition>
  <condition>Gastrointestinal Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This study is a single arm, observational medical device registry designed to establish the&#xD;
        efficacy and safety of treating solid tumours with reversible electroporation. ePORE, CUTIS&#xD;
        and EndoVE are CE marked and are currently being used in the treatment of patients with&#xD;
        solid tumours. This medical device registry will enable the collection of anonymised data&#xD;
        which will enable the analysis and publication of high quality data to continuously support&#xD;
        the efficacy and safety of these devices.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient who has been treated using Calcium Electroporation&#xD;
&#xD;
          -  Any patient who has been treated using Electrochemotherapy&#xD;
&#xD;
          -  Patients must be mentally capable of understanding the information given&#xD;
&#xD;
          -  Patients must give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>SEAN H Kinsella</last_name>
    <role>Study Director</role>
    <affiliation>Mirai Medical</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SEAN H KINSELLA</last_name>
    <phone>+353 91 442 498</phone>
    <email>sean@mirai-medical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Declan Soden</last_name>
    <email>declan@mirai-medical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <zip>E1 1FR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Greme Moir</last_name>
    </contact>
    <investigator>
      <last_name>Greme Moir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 10, 2021</study_first_submitted>
  <study_first_submitted_qc>June 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulsed Electric Fields</keyword>
  <keyword>Reversible Electroporation</keyword>
  <keyword>Electrochemotherapy</keyword>
  <keyword>Ca-Electroporation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 29, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/12/NCT04929912/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

